Gerhardt Attard, MD, PhD, of the Cancer Institute, University College London, presents findings from the phase III AMPLITUDE trial, which looked at the combination of niraparib and abiraterone acetate plus prednisone for patients with metastatic castration-sensitive prostate cancer with alterations ...
Eric Huttenlocher Bent, MD, PhD, of Memorial Sloan Kettering Cancer Center, reviews results from the phase II Metacure trial (cohorts B2 and the B2 expansion), which looked at the efficacy of stereotactic body radiotherapy for PSMA-PET–detected oligometastatic prostate adenocarcinoma (Abstract...
Praful Ravi, MBBChir, MRCP, of Dana-Farber Cancer Institute, presents findings from an ICECaP individual patient-data meta-analysis of randomized controlled trials on a treatment strategy used in high-risk localized prostate cancer (Abstract 5013).
Nicholas D. James, PhD, FRCP, MBBS, of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, describes the use of a multimodal artificial intelligence (AI) model to identify benefit from second-generation androgen receptor pathway inhibitors in patients with high-risk...
Alicia K. Morgans, MD, MPH, FASCO, of Dana-Farber Cancer Institute, discusses health-related quality-of-life data from the phase III ARANOTE trial, which evaluated the androgen receptor inhibitor darolutamide in combination with androgen-deprivation therapy (ADT) vs ADT plus placebo for patients...
Andrew J. Armstrong, MD, MS, of Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, discusses the 5-year overall survival analysis of the ARCHES trial, which investigated enzalutamide plus androgen-deprivation therapy in patients with metastatic...
Michael Schweizer, MD, of the University of Washington and Fred Hutchinson Cancer Center, discusses findings from a randomized dose-expansion study of the investigational EZH2 inhibitor mevrometostat in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer...
Neeraj Agarwal, MD, FASCO, of Huntsman Cancer Institute, presents data from cohort 1 of the phase III TALAPRO-2 trial—final overall survival data, an update on radiographic progression–free survival, and safety follow-up—which included patients with metastatic castration-resistant prostate cancer...
Karim Fizazi, MD, PhD, of Institut Gustave Roussy, University of Paris-Saclay, reviews final overall survival results from cohort 2 of the phase III TALAPRO-2 trial, which investigated the combination of talazoparib and enzalutamide in patients with homologous recombination repair (HRR)-deficient...
William Aronson, MD, of the VA Greater Los Angeles Healthcare System, discusses findings from the CAPFISH-3 trial, which investigated whether a high omega-3, low omega-6 fatty acid diet with fish oil capsules decreased Ki-67 levels in men with prostate cancer on active surveillance (Abstract 312).
Masood Moghul, PhD, of The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, describes the impact of a nurse-led mobile clinical unit on targeted screening invitations to men at high risk for prostate cancer in disadvantaged communities in London (Abstract 317).
Omid Yazdanpanah, MD, of the University of California, Irvine, presents findings from a secondary analysis of the VISION trial, which compared the efficacy and safety of LuPSMA in patients treated with vs without concomitant androgen receptor pathway inhibitors (ARPIs) (Abstract 121).
Nicholas D. James, PhD, FRCP, MBBS, of The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, discusses findings from an embedded phase II randomized study from the STAMPEDE trial. The study assessed the efficacy and toxicity of transdermal estradiol patches vs...
Benjamin Maughan, MD, PharmD, of Huntsman Cancer Institute, discusses the effects of a 12-week, structured, guided exercise program called Personal Optimism With Exercise Recovery (POWER) on fatigue and peak aerobic exercise capacity in patients with advanced prostate cancer receiving...
Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Samuel R. Denmeade, MD, of Johns Hopkins University School of Medicine, discuss a study showing that patients with metastatic castration-resistant prostate whose disease is progressing on abiraterone with androgen-receptor alterations...
Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Karim Fizazi, MD, PhD, of Institut Gustave Roussy and the University of Paris-Saclay, discuss a second interim analysis of the health-related quality of life and pain outcomes in the PSMAfore study (Abstract 5003).
Christos Kyriakopoulos, MD, of the University of Wisconsin Carbone Cancer Center, discusses data suggesting that adding cabazitaxel to abiraterone and prednisone improves progression-free survival in patients with metastatic castration-resistant prostate cancer who previously received chemohormonal ...
Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Susan Halabi, PhD, of the Duke Cancer Institute and Duke University School of Medicine, discuss a clinical-genetic model that identified novel circulating tumor DNA alterations that are prognostic of overall survival and may help to...
Anthony M. Joshua, MBBS, PhD, of Princess Margaret Cancer Centre, discusses results from the MAST study, which explored the question of whether metformin could reduce disease progression in men with low-risk prostate cancer who are undergoing active surveillance (LBA5002).
Sumanta K. Pal, MD, of City of Hope, discusses the ways in which the composition of the gut microbiome may impact the outcome of immune therapy. Methods such as fecal microbiome transplant hold promise as a means of augmenting the effect of treatment and, according to Dr. Pal, potentially...
Umang Swami, MD, of Huntsman Cancer Institute at the University of Utah, describes the molecular and immunologic mechanisms of metastatic tropism in advanced prostate cancer, data that may facilitate future drug development. In patients with metastatic disease, specific sites are associated with...
Maha H.A. Hussain, MD, of the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, discusses phase II findings from the BRCAAway trial. This study showed that in patients with metastatic castration-resistant prostate cancer with BRCA1/2 or ATM alterations, abiraterone and...
Neeraj Agarwal, MD, of Huntsman Cancer Institute at the University of Utah, discusses results of the CONTACT-2 trial, which showed cabozantinib plus atezolizumab improved radiographic progression–free survival of patients with metastatic castration-resistant prostate cancer vs a second novel...
Rana R. McKay, MD, of the University of California, San Diego, discusses phase II findings from the Neptune study of neoadjuvant olaparib plus androgen-deprivation therapy followed by radical prostatectomy in patients with intermediate-risk or high-risk prostate cancer marked by germline or somatic ...
Stephen J. Freedland, MD, of Cedars-Sinai Medical Center, discusses the incidence of prostate cancer in transgender women. Although the rates of disease appear lower than in cisgender men, Dr. Freedland notes the risk is not as limited as case reports may suggest. He also discusses interpreting PSA ...
Samson W. Fine, MD, of Memorial Sloan Kettering Cancer Center, discusses the evolving spectrum of atypical intraductal proliferations in the prostate, from high-grade prostatic intraepithelial neoplasia to intraductal carcinoma. He describes several clinical challenges, including: assessment and...
William J. Catalona, MD, of Northwestern University Feinberg School of Medicine, reviews the genetic landscape in prostate cancer, including BRCA2 and ATM, two important mutations for aggressive disease; the clinical implications of germline testing such as guiding screening and disease management, ...
Alicia K. Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Karim Fizazi, MD, of Institut Gustave Roussy, University of Paris-Saclay, discuss findings from the TALAPRO-2 study, which showed that talazoparib plus enzalutamide improved radiographic progression–free survival over standard-of-care ...
Alicia K. Morgans, MD, MPH, and Praful Ravi, MRCP, MBBChir, both of Dana-Farber Cancer Institute, discuss an individual patient-data analysis of randomized trials from the ICECAP collaborative. A PSA nadir of ≥ 0.1 ng/mL within 6 months after radiotherapy completion was prognostic for prostate...
Alberto Bossi, MD, of Institut Gustave Roussy, discusses phase III findings showing that combining prostate radiotherapy with systemic treatment did not improve overall survival in men with de novo metastatic castration-sensitive prostate cancer and low metastatic burden. However, best outcomes...
This is Part 1 of Novel Hormonal Therapies for Prostate Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Alicia K. Morgans, Neeraj Agarwal, and David VanderWeele discuss biochemical recurrence in prostate cancer. The...
Alex K. Bryant, MD, of the University of Michigan, examined Veterans Administration (VA) facilities in which lower prostate-specific antigen (PSA) screening rates were associated with a subsequent increased incidence of metastatic prostate cancer, particularly among men aged 70 and older. From...
Rahul Aggarwal, MD, of the University of California, San Francisco, discusses recent data from the PRESTO study, which showed that apalutamide plus androgen-deprivation therapy (ADT) for 12 months significantly prolonged PSA progression-free survival compared with ADT alone in patients with...
Sumanta K. Pal, MD, introduces his City of Hope colleagues, Hedyeh Ebrahimi, MD, MPH, who discusses the prevalence of dietary modification and supplement use in patients with metastatic renal cell carcinoma, and Daniela Castro, MSc, who discusses expanding eligibility criteria in kidney, prostate,...
Scott T. Tagawa, MD, of Weill Cornell Medicine, NewYork-Presbyterian Hospital, discusses study results showing that, the anti-PSMA (prostate-specific membrane antigen) monoclonal antibody J591 with ketoconazole and hydrocortisone, when radiolabeled with lutetium-177, leads to improved 18-month...
Alan H. Bryce, MD, of the Mayo Clinic, discusses the final results of the primary endpoint of rPFS and interim results on overall survival among patients with chemotherapy-naive metastatic castration-resistant prostate cancer. The data showed that rucaparib improved radiographic progression-free...
Daniel P. Petrylak, MD, of the Yale Cancer Center, discusses phase III findings from the KEYNOTE-921 study, which was designed to assess the combination of pembrolizumab and docetaxel in the treatment of patients with metastatic castration-resistant prostate cancer. They had not received...
Paul L. Nguyen, MD, of Dana-Farber Cancer Institute and Harvard Medical School, discusses results from the FORMULA-509 study, which compared postoperative salvage radiotherapy and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide, after radical...
Neeraj Agarwal, MD, of the Huntsman Cancer Institute, University of Utah, discusses phase III results from the TALAPRO-2 study, which suggested an improvement in radiographic progression-free survival with the combination of talazoparib and enzalutamide over standard-of-care enzalutamide alone as...
Neal D. Shore, MD, of Carolina Urologic Research Center/Genesis Care, discusses new data from the ENACT trial, which showed that patients with prostate cancer and the RNA biomarkers PAM50 and AR-A were likely to have better outcomes with enzalutamide treatment. The results suggest that such RNA...
Neal D. Shore, MD, of the Carolina Urologic Research Center, discusses his study findings, showing that germline genetic testing influenced care for patients with prostate cancer. Men whose genetic test was positive for a pathogenic germline variant received more recommendations for changes to...
Alicia K. Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Michael S. Hofman, MBBS, of Peter MacCallum Cancer Centre, University of Melbourne, discuss follow-up results on LuPSMA vs cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel...
Alicia K. Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Ian D. Davis, PhD, MBBS, of Monash University and Eastern Health, discuss the latest findings from ANZUP Cancer Trials Group’s ENZAMET cooperative group trial of enzalutamide in patients with metastatic hormone-sensitive prostate...
Matthew R. Smith, PhD, MD, of Massachusetts General Hospital Cancer Center, discusses overall survival findings from the ARASENS trial, which assessed the efficacy of the androgen receptor inhibitor darolutamide vs placebo in combination with androgen-deprivation therapy and docetaxel for patients...
Timothy A. Yap, MBBS, PhD, of The University of Texas MD Anderson Cancer Center, discusses results from the PETRA study, a first-in-class, first-in-human trial of the next-generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2, or RAD51C/D mutations in advanced or metastatic...
Julio M. Pow-Sang, MD, of Moffitt Cancer Center, discusses the treatment landscape for localized prostate cancer and its heterogeneity, the critical importance of stratifying risk to determining treatment options, and the continued improvement of therapy in the field.
Xin Gao, MD, of Massachusetts General Hospital, discusses phase I/II findings on bavdegalutamide, an androgen receptor protein degrader, which showed clinical activity in heavily pretreated patients with metastatic castration-resistant prostate cancer who received one to two prior novel hormonal...
Tanya B. Dorff, MD, of City of Hope National Medical Center, discusses the first-in-human phase I findings showing that prostate stem cell antigen (PSCA) CAR T-cell therapy is feasible in patients with metastatic castration-resistant prostate cancer, with preliminary antitumor activity exhibited.
Neil E. Fleshner, MD, MPH, of the Princess Margaret Cancer Centre, discusses phase II results from the ACDC-RP trial, which indicate a significant tumor response to neoadjuvant abiraterone acetate plus prednisone and leuprolide, with or without cabazitaxel, in patients with high-risk prostate...
Sumanta K. Pal, MD, of City of Hope National Medical Center, discusses some key research developments in kidney cancer, including data on nivolumab and ipilimumab with or without CBM588 in metastatic renal cell carcinoma; intestinal microbiome associated with the development of grade 3 or 4 adverse ...